CA-TIGO
28.3.2024 14:01:28 CET | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the installation and commissioning of a rooftop solar system at its headquarters in California. The system was designed and deployed by Tigo installer partner, Laibach Solar, and has averaged 5% Reclaimed Energy since it was commissioned. Laibach Solar is an employee-owned solar installer in Northern California dedicated to combining high-quality components with unbeatable pricing. It has been a valued installation partner for Tigo since 2018. The installation now contributes to the growth of U.S. corporate solar adoption, which was 14% of the U.S. Solar Market as of 2022, according to the Solar Energy Industries Association.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328503393/en/
The system was designed and deployed by Tigo installer partner Laibach Solar and has averaged 5% Reclaimed Energy since it was commissioned. (Graphic: Business Wire)
The installation is equipped with 180 Tigo TS4-A-O MLPE devices, the Tigo Access Point (TAP), and the Tigo Cloud Connect Advanced (CCA) data logging device. The 90kW system design, which includes 180 500W solar modules and a Solectria inverter, had to overcome significant shading challenges from existing roof features. By deploying its own technology, the performance of the system on the Tigo headquarters will only be minimally impacted by shading throughout the day and be further boosted by Tigo Reclaimed Energy technology. Tigo will also benefit from module-level monitoring and advanced rapid shutdown safety measures to protect solar professionals, building maintenance personnel, and first responders.
“We have used Tigo products on many projects over the years because of the quality and design flexibility they deliver, and it was great to design a system for the Tigo headquarters where we were able to overcome shading constraints from the barrier wall structures with their own technology,” said Dejan Obradovic, owner at Laibach Solar. “While this system is clearly something of a crown jewel for us as a solar installation company, there is no doubt that the pressure is also on, which is why we are using the Energy Intelligence monitoring platform and Tigo EI Professional to keep an eye on things. Tigo is a great partner on our solar mission, and we look forward to many more years of empowering solar with great software and a shared commitment to quality.”
With the Tigo Energy Intelligence monitoring platform, Laibach Solar and Tigo Energy have full control and visibility over the installation. This platform not only allows Tigo to monitor Reclaimed Energy and shading occurrences but also provides optimization insights, ensuring the system operates at its peak efficiency. The Tigo Energy Intelligence Portal gives insight into Reclaimed Energy, or the amount of energy that would have been lost due to shading and any module mismatch. On typical sunny days, the rooftop system at the Tigo headquarters is projected to reclaim an average of approximately 14kWh, daily.
“I want to thank the team at Laibach Solar for the great system design and a very high-quality installation, particularly as it relates to overcoming a tricky combination of shading and permitting constraints,” said Jing Tian, chief growth officer at Tigo Energy. “With the setup we have today, our solar output is being optimized to give us the best possible gain in the form of Reclaimed Energy, which helps us constantly shave off of the power demand we would have for the grid. This system is exactly the kind of result that a commitment to Total Quality Solar can produce.”
In the spirit of the timeless manufacturing principles of Total Quality Management, Total Quality Solar (TQS) is a principle that guides a continual process of detecting and reducing errors in the design, installation, and equipment throughout the solar ecosystem.
To learn more about the Tigo Energy Intelligence platform, sign up for a custom demo here. To inquire about products, contact the sales team here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328503393/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
